

Leading Driver In The Evkeeza Market 2025: Increasing Drug Approvals On The Growth Of Market

The Business Research Company's Evkeeza Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 6, 2025

[/Einpresswire.com/](https://www.einpresswire.com/) -- Unveiling the 2025 Market Reports: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The logo for The Business Research Company, featuring the text "The Business Research Company" in a black, sans-serif font. To the right of the text is a stylized bar chart with four bars of varying heights, colored in shades of green and blue.

The Business
Research Company

Evkeeza Market Report 2025

What Is the Historical Progress and Projected Growth of the [Evkeeza Market](#)?

- The Evkeeza market has experienced notable expansion in recent years.
- In 2024, the market was valued at \$XX million.
- By 2025, it is projected to grow to \$XX million, registering a CAGR of XX%.
- Key drivers of past growth include:
 - o Supportive regulatory frameworks and policies
 - o Rapid advancements in genomics and personalized medicine
 - o An aging population contributing to increased demand
 - o Government initiatives promoting drug accessibility
 - o The emergence of genetic conditions and birth defects

How Is the Evkeeza Market Expected to Evolve in the Future?

- The market is forecasted to expand at a CAGR of XX% over the coming years.
- By 2029, it is anticipated to reach \$XX million.
- Factors fueling this growth include:
 - o Rising cases of hypercholesterolemia
 - o Increasing prevalence of rare diseases worldwide
 - o A growing burden of rare neurological disorders
 - o Higher healthcare expenditure and investment in rare disease treatment
- Expected trends influencing the market include:
 - o Development of specialized medications for rare conditions
 - o Expansion of personalized medicine approaches

- o Integration of telemedicine and remote patient monitoring
- o Growth of patient support programs
- o Regulatory approvals facilitating drug accessibility

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20070&type=smp>

What Are the Significant Market Drivers in the [Evkeeza Industry](#)?

A key driver of growth in the Evkeeza market is the increasing prevalence of genetic disorders, which has heightened demand for effective treatment solutions. Genetic disorders arise due to mutations in DNA or chromosomal abnormalities, and advancements in diagnostic technologies have led to more frequent detection.

Evkeeza is specifically used to treat homozygous familial hypercholesterolemia (HoFH), a genetic disorder causing high LDL cholesterol levels, by inhibiting ANGPTL3. The American Society of Hematology predicts that the global population affected by sickle cell disease (SCD) will rise by nearly 30% by 2050, further highlighting the rising burden of genetic disorders and the growing demand for treatments like Evkeeza.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/evkeeza-global-market-report>

Who Are the Leading Players in the Evkeeza Market?

A key player in the Evkeeza market is Regeneron Pharmaceuticals Inc., which plays a crucial role in market expansion through continuous innovation and strategic initiatives.

What Are the Emerging Trends in the Evkeeza Market?

One of the major trends in the Evkeeza market is the growing number of regulatory approvals, which help expand the reach of treatments for homozygous familial hypercholesterolemia (HoFH).

For instance, in March 2023, the FDA approved Evkeeza (evinacumab-dgnb), an ANGPTL3 inhibitor developed by Regeneron Pharmaceuticals Inc., for children aged 5 to 11 years with HoFH. This approval marked a significant milestone, providing a new treatment option for approximately 1,300 affected individuals in the U.S.. Clinical studies demonstrated that Evkeeza, in combination with other lipid-lowering therapies, achieved an average LDL-C reduction of 48% within 24 weeks.

How Is the Evkeeza Market Segmented?

The Evkeeza market is categorized based on:

- By Indication:
 - o Primary Hypercholesterolemia
 - o Homozygous Familial Hypercholesterolemia

- By Route of Administration:
 - o Intravenous (IV) Infusion
 - o Self-Administration
 - o Subcutaneous (SC) Administration
 - o Hospital Infusion Centers
 - o Infusion in Ambulatory Care Settings
- By Distribution Channel:
 - o Hospital Pharmacies
 - o Specialty Pharmacies
 - o Online Pharmacies

Which Regions Dominate the Evkeeza Market?

In 2024, North America held the largest market share. However, Asia-Pacific is projected to be the fastest-growing region during the forecast period. The report provides insights into multiple regions, including Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse For More Similar Reports-

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report>

Pharmaceutical API Manufacturing Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report>

Alpha Mannosidosis Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report>

Learn More About [The Business Research Company](#)

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/791649943>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.